Regulus Therapeutics Inc. has expanded its development of RG-101, a GalNAc-conjugated anti-miR that targets miR-122, through a clinical trial collaboration and formulation development agreement with GlaxoSmithKline. The companies plan to conduct a Phase II study to evaluate the combination of RG-101 and GSK2878175, an investigational non-nucleoside NS5B polymerase inhibitor, for the treatment of HCV.   GSK will also work on developing a long-acting parenteral for injection (LAP) formulation of...